Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT05755386

PHASE3

Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN

Sponsor: Novartis Pharmaceuticals

View on ClinicalTrials.gov

Summary

This study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis.

Official title: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iptacopan (LNP023) in Idiopathic Immune-complex-mediated Membranoproliferative Glomerulonephritis (IC-MPGN)

Key Details

Gender

All

Age Range

12 Years - 60 Years

Study Type

INTERVENTIONAL

Enrollment

106

Start Date

2023-10-02

Completion Date

2029-05-31

Last Updated

2026-04-01

Healthy Volunteers

Conditions

IC-MPGN

Interventions

DRUG

Placebo

Placebo to iptacopan 200mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)

DRUG

iptacopan

iptacopan 200 mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)

Inclusion Criteria: * Male and female patients including adults (aged at least 18 years to ≤ 60 years) and adolescents (12 -17 years in non-EU countries at screening and 16-17 years in EU countries at screening). * Diagnosis of idiopathic IC-MPGN as confirmed by kidney biopsy within 12 months prior to screening in adults and within 3 years of screening in adolescents (a biopsy report, review and confirmation by the Investigator is required). If such a biopsy is not available in an adult participant, this must be obtained at screening (performed and assessed locally for adults only). * Prior to randomization, all participants must have been on a maximally recommended or tolerated dose of renin angiotensin system inhibitors (RASi), e.g an ACEi or ARB for at least 90 days (or as according to local guidelines). The doses of other drugs administered to reduce proteinuria and control the disease including mycophenolic acids (MPAs - mycophenolate mofetil or mycophenolate sodium), corticosteroids, SGLT2 inhibitors and mineralocorticoid receptor antagonists should be stable for at least 90 days prior to randomization * UPCR ≥ 1.0 g/g (≥ 113 mg/mmol) sampled from the first morning void urine sample at Day -75 and Day -15 * Estimated GFR (using the chronic kidney disease \[CKD\]-EPI formula for adult participants and modified Schwartz formula for adolescents aged 12 to 17 years) or measured GFR ≥ 30 ml/min/1.73m2 at screening and Day -15. * Mandatory vaccination against Neisseria meningitidis and Streptococcus pneumoniae infection prior to the start of study treatment. If the participant has not been previously vaccinated, or if a booster is required, the vaccine should be given according to local regulations at least 2 weeks prior to the first administration of study treatment. If the study treatment has to start earlier than 2 weeks post vaccination, prophylactic antibiotic treatment should be initiated in accordance with local standard of care. * If not previously vaccinated, or if a booster is required, vaccination against Haemophilus influenzae infections should be given, if available and according to local regulations, at least 2 weeks prior to the first study treatment administration. Exclusion Criteria: * Participants who have undergone cell or solid organ transplantation, including kidney transplantation. * Participants diagnosed with secondary IC-MPGN including but not limited to any of the following conditions: * Deposition of antigen-antibody immune complexes as a result of any chronic infections, including * Hepatitis C virus (HCV) including HCV-associated mixed cryoglobulinemia, hepatitis B virus (HBV); * Bacterial-endocarditis, infected ventriculo-atrial shunt, visceral abscesses, leprosy, meningococcal meningitis; chronic bacterial infections * Protozoa/other infections- malaria, schistosomiasis, mycoplasma, leishmaniasis, filariasis, histroplasmosis Renal deposition of immune complexes as a result of a systemic autoimmune disease: * Systemic lupus erythematosus (SLE) * Sjögren syndrome * Rheumatoid arthritis * Mixed connective tissue disease Deposition of monoclonal immunoglobulins because of a monoclonal gammopathy due to plasma cell or B cell disorders. Monoclonal gammopathy of undetermined significance (MGUS) confirmed by the measurement of serum free light chains or other investigation as per local standard of care. Fibrillary glomerulonephritis * Rapidly progressive crescentic glomerulonephritis defined as a 50% decline in the eGFR within 3 months with kidney biopsy findings of glomerular crescent formation seen in at least 50% of glomeruli on the most recent biopsy. * Kidney biopsy showing interstitial fibrosis/tubular atrophy (IF/TA) of more than 50%. * Participants with an active systemic bacterial, viral or fungal infection within 14 days prior to study treatment administration or the presence of fever ≥ 38°C (100.4°F) within 7 days prior to study treatment administration. * A history of recurrent invasive infections caused by encapsulated organisms, e.g., Neisseria meningitidis and Streptococcus pneumoniae. * The use of inhibitors of complement factors (e.g., Factor B, Factor D, complement 3 (C3) inhibitors, anti-Complement 5 (C5) antibodies, C5a receptor antagonists) within 3 months or 5 half-lives prior to the Screening visit. * The use of immunosuppressants (except MPAs), cyclophosphamide or systemic corticosteroids at a dose \>7.5 mg/day (or equivalent for a similar corticosteroid medication) within 90 days of study drug administration. * The use of MPAs is not permitted within 90 days prior to randomization in India, as per the local health authority requirement. * Acute post-infectious glomerulonephritis at screening, based upon the opinion of the investigator. * Body mass index (BMI) \>38 kg/m2 at screening and randomization. Body weight \<35 kg at screening and randomization

Locations (124)

Ronald Reagan UCLA Medical Center

Los Angeles, California, United States

Univ Cali Irvine ALS Neuromuscular

Orange, California, United States

UCSF

San Francisco, California, United States

Olive View UCLA Medical Center

Sylmar, California, United States

Childrens Hospital Colorado

Aurora, Colorado, United States

Nicklaus Childrens Hospital

Miami, Florida, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Boston Univ School of Medicine

Boston, Massachusetts, United States

University of Minnesota

Minneapolis, Minnesota, United States

Washington University in St Louis

St Louis, Missouri, United States

University of New Mexico

Albuquerque, New Mexico, United States

Col Uni Med Center New York Presby

New York, New York, United States

University Of Cincinnati

Cincinnati, Ohio, United States

OHSU Dept of Nephrology

Portland, Oregon, United States

Univ of Pennsylvania Medical Center

Philadelphia, Pennsylvania, United States

UT Southwestern Medical Center

Dallas, Texas, United States

Prolato Clinical Research Center

Houston, Texas, United States

Baylor Scott and White Research

Temple, Texas, United States

University of Utah

Salt Lake City, Utah, United States

University of Wisconsin

Madison, Wisconsin, United States

Novartis Investigative Site

CABA, Buenos Aires, Argentina

Novartis Investigative Site

CABA, Buenos Aires, Argentina

Novartis Investigative Site

Buenos Aires, Argentina

Novartis Investigative Site

CABA, Argentina

Novartis Investigative Site

Santa Fe, Argentina

Novartis Investigative Site

Fortaleza, Ceará, Brazil

Novartis Investigative Site

Brasília, Federal District, Brazil

Novartis Investigative Site

Belo Horizonte, Minas Gerais, Brazil

Novartis Investigative Site

Recife, Pernambuco, Brazil

Novartis Investigative Site

Niterói, Rio de Janeiro, Brazil

Novartis Investigative Site

Rio de Janeiro, Rio de Janeiro, Brazil

Novartis Investigative Site

Natal, Rio Grande do Norte, Brazil

Novartis Investigative Site

Porto Alegre, Rio Grande do Sul, Brazil

Novartis Investigative Site

Botucatu, São Paulo, Brazil

Novartis Investigative Site

Santo André, São Paulo, Brazil

Novartis Investigative Site

Sao Jose Rio Preto, São Paulo, Brazil

Novartis Investigative Site

São Paulo, São Paulo, Brazil

Novartis Investigative Site

São Paulo, São Paulo, Brazil

Novartis Investigative Site

São Paulo, São Paulo, Brazil

Novartis Investigative Site

Salvador, Brazil

Novartis Investigative Site

Etobicoke, Ontario, Canada

Novartis Investigative Site

Toronto, Ontario, Canada

Novartis Investigative Site

Montreal, Quebec, Canada

Novartis Investigative Site

Montreal, Quebec, Canada

Novartis Investigative Site

Prague, Czechia

Novartis Investigative Site

Aarhus N, Denmark

Novartis Investigative Site

Copenhagen, Denmark

Novartis Investigative Site

Marseille, France

Novartis Investigative Site

Montpellier, France

Novartis Investigative Site

Paris, France

Novartis Investigative Site

Rennes, France

Novartis Investigative Site

Toulouse, France

Novartis Investigative Site

Munich, Bavaria, Germany

Novartis Investigative Site

Würzburg, Bavaria, Germany

Novartis Investigative Site

Dresden, Saxony, Germany

Novartis Investigative Site

Jena, Thuringia, Germany

Novartis Investigative Site

Berlin, Germany

Novartis Investigative Site

Essen, Germany

Novartis Investigative Site

Hamburg, Germany

Novartis Investigative Site

Hanover, Germany

Novartis Investigative Site

Mainz, Germany

Novartis Investigative Site

Ulm, Germany

Novartis Investigative Site

Athens, Greece

Novartis Investigative Site

Chaïdári, Greece

Novartis Investigative Site

Heraklion Crete., Greece

Novartis Investigative Site

Ioannina, Greece

Novartis Investigative Site

Pátrai, Greece

Novartis Investigative Site

Thessaloniki, Greece

Novartis Investigative Site

Bangalore, Karnataka, India

Novartis Investigative Site

Nagpur, Maharashtra, India

Novartis Investigative Site

Pune, Maharashtra, India

Novartis Investigative Site

New Delhi, National Capital Territory of Delhi, India

Novartis Investigative Site

Hyderabad, Telangana, India

Novartis Investigative Site

Haifa, Israel

Novartis Investigative Site

Jerusalem, Israel

Novartis Investigative Site

Petah Tikva, Israel

Novartis Investigative Site

Bari, BA, Italy

Novartis Investigative Site

Ranica, BG, Italy

Novartis Investigative Site

Brescia, BS, Italy

Novartis Investigative Site

Milan, MI, Italy

Novartis Investigative Site

Roma, RM, Italy

Novartis Investigative Site

Torino, TO, Italy

Novartis Investigative Site

Naples, Italy

Novartis Investigative Site

Fuchū, Tokyo, Japan

Novartis Investigative Site

Hachiōji, Tokyo, Japan

Novartis Investigative Site

Okayama, Japan

Novartis Investigative Site

Osaka, Japan

Novartis Investigative Site

Groningen, Netherlands

Novartis Investigative Site

Poznan, Greater Poland Voivodeship, Poland

Novartis Investigative Site

Bialystok, Poland

Novartis Investigative Site

Krakow, Poland

Novartis Investigative Site

Olsztyn, Poland

Novartis Investigative Site

Warsaw, Poland

Novartis Investigative Site

Warsaw, Poland

Novartis Investigative Site

Wroclaw, Poland

Novartis Investigative Site

Martin, Slovakia, Slovakia

Novartis Investigative Site

Košice, Slovakia

Novartis Investigative Site

Seoul, Korea, South Korea

Novartis Investigative Site

Seoul, South Korea

Novartis Investigative Site

Pamplona, Navarre, Spain

Novartis Investigative Site

Almería, Spain

Novartis Investigative Site

Barcelona, Spain

Novartis Investigative Site

Barcelona, Spain

Novartis Investigative Site

Madrid, Spain

Novartis Investigative Site

Madrid, Spain

Novartis Investigative Site

Madrid, Spain

Novartis Investigative Site

Salamanca, Spain

Novartis Investigative Site

Bern, Switzerland

Novartis Investigative Site

Lausanne, Switzerland

Novartis Investigative Site

Zurich, Switzerland

Novartis Investigative Site

Kaohsiung City, Taiwan

Novartis Investigative Site

Istanbul, Fatih, Turkey (Türkiye)

Novartis Investigative Site

Izmir, Karsiyaka, Turkey (Türkiye)

Novartis Investigative Site

Köseköy, Kocaeli, Turkey (Türkiye)

Novartis Investigative Site

Kayseri, Melikgazi, Turkey (Türkiye)

Novartis Investigative Site

Ankara, Yenimahalle, Turkey (Türkiye)

Novartis Investigative Site

Mersin, Yenisehir, Turkey (Türkiye)

Novartis Investigative Site

Belfast, United Kingdom

Novartis Investigative Site

Cardiff, United Kingdom

Novartis Investigative Site

London, United Kingdom

Novartis Investigative Site

London, United Kingdom

Novartis Investigative Site

Manchester, United Kingdom

Novartis Investigative Site

Salford, United Kingdom

Novartis Investigative Site

Ho Chi Minh City, Vietnam

Clinical Research Directory

Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN

Summary

Key Details

Conditions

Interventions

Eligibility Criteria

Locations (124)